Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Tanuma, Junko ^a   Sano, Kazumi ^b   Teruya, Katsuji ^a   Watanabe, Koji ^a   Aoki, Takahiro ^a   Honda, Haruhito ^a   Yazaki, Hirohisa ^a   Tsukada, Kunihisa ^a   Gatanaga, Hiroyuki ^a   Kikuchi, Yoshimi ^a   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LOPINAVIR PLUS RITONAVIR; RIFABUTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MYCOBACTERIOSIS;

ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; RIFABUTIN; RITONAVIR; YOUNG ADULT;

EID: 84881087932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070611     Document Type: Article

References (24)

1. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society (2003) AmericanThoracicSociety/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 6: 603-662.
2. Pfizer, Inc. Mycobutin (rifabutin) prescribing information. Pfizer, Inc., New York, NY. Available: http://www.pfizer.com/files/products/uspi_mycobutin.pdf. Accessed 2012 August 21.
3. Centers for Disease Control and Prevention (2009) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 58: 1-207.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. Available: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 2012 August 21.
5. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, et al. (2004) Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol 44: 305-313.
6. Ford SL, Chen YC, Lou Y, Borland J, Min SS, et al. (2008) Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 52: 534-538.
7. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, et al. (2009) Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 49: 1305-1311.
8. Zhang X, Fettner S, Zwanziger E, Rowell L, Salgo M, et al. (2011) Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrob Agents Chemother 55: 680-687.
9. Centers for Disease Control and Prevention (1994) Uveitis associated with rifabutin therapy. MMWR 43: 658.
10. Shafran SD, Singer J, Zarowny DP, Deschênes J, Phillips P, et al. (1998) Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 177: 252-255.
11. Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, et al. (2011) Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother 66: 2075-2082.
12. Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, et al. (2010) Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 54: 4440-4445.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3: 1-139. Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2012 August 21.
14. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, et al. (2005) Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40: 1481-1491.
15. Jenny-Avital ER, Joseph K, (2009) Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 48: 1471-1474.
16. Li J, Munsiff SS, Driver CR, Sackoff J, (2005) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City. 1997-2000. Clin Infect Dis 41: 83-91.
17. Khachi H, O'Connell R, Ladenheim D, Orkin C, et al. (2009) Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 64: 871-873.
18. Gomez A, Ingelman-Sundberg M, (2009) Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 85: 426-430.
19. Lee IS, Kim D, (2011) Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch Pharm Res 34: 1799-1816.
20. Kunin CM, (1996) Antimicrobial activity of rifabutin. Clin Infect Dis 22: S3-13.
21. Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, et al. (1989) Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 33: 1237-1241.
22. Blaschke TF, Skinner MH, (1996) The clinical pharmacokinetics of rifabutin. Clin Infect Dis 22: S15-21.
23. Strolin Benedetti M, Efthymiopoulos C, Sassella D, Moro E, Repetto M, (1990) Autoinduction of rifabutin metabolism in man. Xenobiotica 20: 1113-1119.
24. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, et al. (2003) Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Tuberculosis Trials Consortium. Am J Respir Crit Care Med 167: 1341-1347.